Navigation Links
WellSpring Pharmaceutical Corp. Acquires Consumer Product Brands from McNeil Consumer Healthcare -- Deal Enhances US and Canadian Pharmaceutical Business
Date:9/2/2008

BRADENTON, Fla. and OAKVILLE, Ontario, Sept. 2 /PRNewswire/ -- WellSpring Pharmaceutical Corporation, a growing North American-based pharmaceutical manufacturer, today announced expansion of its consumer health care product line by concluding a transaction with McNeil Consumer Healthcare Division of McNeil PPC, Inc. wherein WellSpring has purchased several popular over-the-counter (OTC) consumer drug products. In an all cash transaction, WellSpring has purchased the US rights to Micatin (R) (antifungal), Emetrol (R) (anti-nausea), and Gelusil (R) (antacid), and the Canadian rights to Micatin, Gelusil, and Glycerin Suppositories (laxative). The purchase price was not disclosed.

The acquisition of these brands further strengthens WellSpring's consumer product business in Canada where they join Glaxal Base (TM), Barriere (R) (skin care products), Dequadin (R) (cough/cold), Replens (R) (vaginal moisturizer), K-Lyte (R) (potassium supplement), and others. In the US the new brands give WellSpring a base in the consumer healthcare marketplace soon to be joined by the launch of Glaxal Base and Barriere.

"With consumers taking more responsibility for their own health, this segment of the pharmaceutical market holds substantial promise for growth," said Dr. Robert A. Vukovich, WellSpring's President and CEO. "Having marketed OTC products in Canada for many years, our experience in growing this pharmaceutical category should prove to be very beneficial. WellSpring expects to undertake an aggressive marketing effort to re-invigorate these products and expand their distribution," Dr. Vukovich said.

WellSpring Pharmaceutical Corp. has made the development, marketing and sales of new and novel prescription and OTC drug products its strategic focus. WellSpring's prescription drug products include Dyrenium(R) (diuretic) and Dibenzyline(R) (anti-hypertension) which are marketed in the US. The firm is an active acquirer of pharmaceutical brands and enhances their value through the development of product improvements and line extensions.

WellSpring is a privately held pharmaceutical company founded in 1999 by Dr. Robert A. Vukovich the firm's CEO and Chairman. Dr. Vukovich previously founded and managed Roberts Pharmaceutical Corporation of Eatontown, NJ until its acquisition by Shire Pharmaceutical Group in 1999. WellSpring owns and operates an FDA approved manufacturing plant in Oakville, Ontario, Canada. Its administrative headquarters are located in Bradenton, Florida. The firm provides contract manufacturing services to the pharmaceutical industry and manufactures prescription and OTC drug products for both the US and Canada.

Press - Dr. Robert A. Vukovich, +1-941-552-7880, or +1-941-504-1229, or Wendy Shusko, +1-941-552-7881. Canada: Bonnie Feeney +1-905-337-4500.

WellSpring Websites: http://www.wellspringpharm.com, http://www.wpcoutsourcing.com, http://www.wellskin.ca.

Information regarding several of the newly acquired brands can be found at the following web addresses: http://www.micatin.com and http://www.emetrol.com.


'/>"/>
SOURCE WellSpring Pharmaceutical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
3. Indonesias Pharmaceutical companies Get Boost in Competitive Advantage from Launch of Newport Horizon Premium and IDRAC Solutions by Thomson Reuters
4. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
5. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
6. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
7. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
8. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
9. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
10. MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
11. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology: